Fonseca R, Stewart AK . Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther 2007; 6: 802–810. ArticleCASPubMed Google Scholar
San-Miguel J, Harousseau JL, Joshua D, Anderson KC . Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008; 26: 2761–2766. ArticleCASPubMed Google Scholar
Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF . New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008; 9: 1157–1165. ArticleCASPubMed Google Scholar
Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC . Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 2008; 49: 1238–1245. ArticleCASPubMed Google Scholar
Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008; 8: 1053–1072. ArticleCASPubMed Google Scholar
Argyriou AA, Iconomou G, Kalofonos HP . Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593–1599. ArticleCASPubMed Google Scholar
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414–423. ArticleCASPubMed Google Scholar
Bommert K, Bargou RC, Stuhmer T . Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 1574–1580. ArticleCASPubMed Google Scholar
Kawano MM, Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ et al. Growth mechanism of human myeloma cells by interleukin-6. Int J Hematol 2002; 76 (Suppl 1): 329–333. ArticlePubMed Google Scholar
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105–115. ArticleCASPubMed Google Scholar
Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212–2221. CASPubMed Google Scholar
Bharti AC, Donato N, Aggarwal BB . Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863–3871. ArticleCASPubMed Google Scholar
Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 2005; 93: 70–80. ArticleCASPubMedPubMed Central Google Scholar
De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109: 823–828. ArticleCASPubMed Google Scholar
Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 2006; 66: 9714–9721. ArticleCASPubMed Google Scholar
Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 2009; 8: 26–35. ArticleCASPubMedPubMed Central Google Scholar
Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16: 487–497. ArticleCASPubMedPubMed Central Google Scholar
Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A, Thompson LM et al. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PloS one 2008; 3: e3961. ArticlePubMedPubMed Central Google Scholar
Heale BS, Soifer HS, Bowers C, Rossi JJ . siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res 2005; 33: e30. ArticlePubMedPubMed Central Google Scholar
Scherer LJ, Yildiz Y, Kim J, Cagnon L, Heale B, Rossi JJ . Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes. Mol Ther 2004; 10: 597–603. ArticleCASPubMed Google Scholar
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295–303. ArticleCASPubMed Google Scholar
Chou TC . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621–681. ArticleCASPubMed Google Scholar
Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP, Anderson KC . Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res 1997; 3: 1017–1022. CASPubMed Google Scholar
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F . Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374 (Part 1): 1–20. ArticleCASPubMedPubMed Central Google Scholar
Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L . Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334 (Part 2): 297–314. ArticleCASPubMedPubMed Central Google Scholar
Zhang B, Fenton RG . Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2). J Cell Physiol 2002; 193: 42–54. ArticleCASPubMed Google Scholar
Puthier D, Bataille R, Amiot M . IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999; 29: 3945–3950. ArticleCASPubMed Google Scholar
Meads MB, Hazlehurst LA, Dalton WS . The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14: 2519–2526. ArticleCASPubMed Google Scholar
Nefedova Y, Landowski TH, Dalton WS . Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17: 1175–1182. ArticleCASPubMed Google Scholar
Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729–736. ArticleCASPubMed Google Scholar
Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260–264. ArticleCASPubMedPubMed Central Google Scholar
Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575. ArticleCASPubMed Google Scholar
Grigorieva I, Thomas X, Epstein J . The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 1998; 26: 597–603. CASPubMed Google Scholar
Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI . Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004; 103: 3503–3510. ArticleCASPubMed Google Scholar
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J . Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296–303. ArticleCASPubMedPubMed Central Google Scholar
Yang Y, Ochando J, Yopp A, Bromberg JS, Ding Y . IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation. J Immunol 2005; 174: 2720–2729. ArticleCASPubMed Google Scholar
Schaper F, Gendo C, Eck M, Schmitz J, Grimm C, Anhuf D et al. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem J 1998; 335 (Part 3): 557–565. ArticleCASPubMedPubMed Central Google Scholar
Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. Embo J 1995; 14: 1421–1429. ArticleCASPubMedPubMed Central Google Scholar
Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191–199. ArticleCASPubMed Google Scholar
Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000; 97: 228–233. ArticleCASPubMedPubMed Central Google Scholar
Wen XY, Stewart AK, Sooknanan RR, Henderson G, Hawley TS, Reimold AM et al. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells. Int J Oncol 1999; 15: 173–178. CASPubMed Google Scholar
Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19: 1248–1252. ArticleCASPubMed Google Scholar
Zhang B, Gojo I, Fenton RG . Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885–1893. ArticleCASPubMed Google Scholar
Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 2001; 7: 4262–4271. CASPubMed Google Scholar
Jourdan M, Veyrune JL, De Vos J, Redal N, Couderc G, Klein B . A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003; 22: 2950–2959. ArticleCASPubMedPubMed Central Google Scholar
Zhou Q, Yao Y, Ericson SG . The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells. Int J Hematol 2004; 79: 63–73. ArticleCASPubMed Google Scholar
Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, Maekawa T et al. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 2007; 6: 987–994. ArticleCASPubMed Google Scholar
Zhang B, Potyagaylo V, Fenton RG . IL-6-independent expression of Mcl-1 in human multiple myeloma. Oncogene 2003; 22: 1848–1859. ArticleCASPubMed Google Scholar
Podar K, Chauhan D, Anderson KC . Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10–24. ArticleCASPubMed Google Scholar
Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002; 100: 3311–3318. ArticleCASPubMed Google Scholar
Alas S, Bonavida B . Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316–326. CASPubMed Google Scholar
Krejci P, Murakami S, Prochazkova J, Trantirek L, Chlebova K, Ouyang Z et al. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J Biol Chem 2010; 285: 20644–20653. ArticleCASPubMedPubMed Central Google Scholar
Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008; 112: 5095–5102. ArticleCASPubMedPubMed Central Google Scholar
Ronchetti D, Greco A, Compasso S, Colombo G, Dell’Era P, Otsuki T et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001; 20: 3553–3562. ArticleCASPubMed Google Scholar
Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010; 29: 1190–1202. ArticleCASPubMed Google Scholar
Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z . Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PloS One 2010; 5: e11859. ArticlePubMedPubMed Central Google Scholar
Chebel A, Kagialis-Girard S, Catallo R, Chien WW, Mialou V, Domenech C et al. Indirubin derivatives inhibit malignant lymphoid cell proliferation. Leuk Lymphoma 2009; 50: 2049–2060. ArticleCASPubMed Google Scholar